Outlook Therapeutics announces FDA approval of Lytenava for wet AMD

Outlook Therapeutics (OTLK) announced that the Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD. “The approval establishes Lytenava as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States,” the company said in a statement. It adds, “Outlook Therapeutics believes this FDA approval establishes a new benchmark for ophthalmic bevacizumab and positions Lytenava to become the new FDA-approved standard for bevacizumab therapy in patients with wet AMD. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care.” Outlook expects to make Lytenava available to eligible patients in the United States before year-end.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Outlook Therapeutics announces FDA approval of Lytenava for wet AMD

Other newsrooms on this story

Related reading

FDA approves Lytenava for wet AMD

Outlook Therapeutics Eye Drug Review Returns To FDA — Again - Outlook…

Outlook Therapeutics resubmits biologics license application for ONS-5010

FDA Approves Branded Bevacizumab for Wet AMD

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook…

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for…